Currently, low-dose IL-2 therapy tried to treat various autoimmune diseases including RA, primary Sjögren's syndrome and SLE, has been shown to increase the number of CD4+CD25+FOXP3+Treg cells and achieved therapeutic results [24, 42, 45]. Here, FOXP3 is linked to Sjogren syndrome.